Horizon announces FDA label update for thyroid eye disease therapy
Bet_Noire

Horizon Therapeutics (NASDAQ:HZNP) announced Friday that the FDA approved an update to the labeling information of the company's thyroid eye disease (TED) therapy Tepezza related to its indications and usage.
Accordingly, the FDA has cleared Tepezza use for "Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration," HZNP, which struck a buyout deal with Amgen (AMGN) late last year, said.

"The updated indication reinforces the importance of unrestricted access for all eligible patients across the full spectrum of Thyroid Eye Disease," Chief Executive of Horizon (HZNP) Tim Walbert remarked.

The label update comes after the company announced topline data from a Phase 4 trial for Tepezza in TED early this week, noting that the trial reached the primary endpoint with a statistically significant reduction in TED symptom proptosis.